Table 3.

Summary of the results.

Disease	[5pt]ANCA-associated vasculitis	[5pt]Antiphospholipid syndrome	[5pt]Autoimmune hemolytic anemia	[5pt]Autoimmune hepatitis	[5pt]Behçet's disease	[5pt]Bullous pemphigoid	[5pt]C1-INH-AAE*	[5pt]Castleman's disease	[5pt]Cryoglobulinemia	[5pt]Goodpasture's disease	[5pt]Graves' disease	[5pt]IgA nephropathy	[5pt]IgG4-related disease	[5pt]Immune thrombocytopenia	[5pt]Inflammatory myositis	[5pt]Juvenile idiopathic arthritis	[5pt]Membraneous nephropathy	[5pt]Multiplesclerosis		[5pt]Myasthenia gravis	[5pt]Nephrotic syndrome	[5pt]Neuromyelitis optica	[5pt]Pemphigus	[5pt]Rheumathoid arthritis	[5pt]Sjörgen's syndrome	[5pt]Spondyloarthropathy	[5pt]Systemic lupus erythematosus	[5pt]Systemic sclerosis	[5pt]Ulcerative colitis
																		PPMS	RRMS
Level I
Level IIa
Level IIb
Level IIIa
Level IIIb
Level IV
Too little information
Legend
Level I	Approved by FDA/EMA
Level IIa	Multicentric double-blind RCTs proving a significant superiority over standard-of-care treatment
Level IIb	Multicentric double-blind RCTs proving a significant superiority over placebo
Level IIIa	Clinical study, not fulfilling the above-mentioned criteria, but proving a superiority over standard-of-care treatment
Level IIIb	Clinical study, not fulfilling the above mentioned-criteria, but proving a superiority over placebo
Level IV	Case series or open-label trials without control group with positive results
Achieved
Failed
Mixed result

^*Acquired angioedema with C1-inhibitor deficiency.